Literature DB >> 30087428

CT textural analysis of gastric cancer: correlations with immunohistochemical biomarkers.

Shunli Liu1, Hua Shi1, Changfeng Ji1, Wenxian Guan2, Ling Chen3, Yingshi Sun4, Lei Tang4, Yue Guan5, Weifeng Li5, Yun Ge5, Jian He6, Song Liu7, Zhengyang Zhou8.   

Abstract

To investigate the ability of CT texture analysis to assess and predict the expression statuses of E-cadherin, Ki67, VEGFR2 and EGFR in gastric cancers, the enhanced CT images of 139 patients with gastric cancer were retrospectively reviewed. The region of interest was manually drawn along the margin of the lesion on the largest slice in the arterial and venous phases, which yielded a series of texture parameters. Our results showed that the standard deviation, width, entropy, entropy (H), correlation and contrast from the arterial and venous phases were significantly correlated with the E-cadherin expression level in gastric cancers (all P < 0.05). The skewness from the arterial phase and the mean and autocorrelation from the venous phase were negatively correlated with the Ki67 expression level in gastric cancers (all P < 0.05). The width, entropy and contrast from the venous phase were positively correlated with the VEGFR2 expression level in gastric cancers (all P < 0.05). No significant correlation was found between the texture features and EGFR expression level. CT texture analysis, which had areas under the receiver operating characteristic curve (AUCs) ranging from 0.612 to 0.715, holds promise in predicting E-cadherin, Ki67 and VEGFR2 expression levels in gastric cancers.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30087428      PMCID: PMC6081398          DOI: 10.1038/s41598-018-30352-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Gastric cancer is the fifth most common cancer and the third leading cause of cancer death worldwide, although the incidence and mortality rates have been recently declining[1]. Most gastric cancer patients have an advanced stage of disease at the time of diagnosis, and the treatment options are limited, especially for patients with an M1 or a T4b stage[2]. Therefore, exploring new therapeutic options and identifying subgroups of patients who may benefit from special treatments has been a focal point of research. Great effort should be made in the research of biological molecular markers to determine the ability of tumour migration, proliferation and angiogenesis in gastric cancer. E-cadherin is the main adhesion molecule of epithelia and has been implicated in carcinogenesis due to its frequent loss in human epithelial cancers[3]. According to previous studies, E-cadherin plays a vital role in the infiltration and metastasis of gastric cancer, and a negative expression of E-cadherin might be a predictive factor for a poor prognosis for gastric cancer[4]. Ki67 is a nuclear protein involved in cell proliferation regulation and is expressed in all phases of the cell cycle, except for the G0 phase[5]. Ki67 is usually recognized as a useful marker for the proliferation of tumour cells and has been a valuable prognostic and predictive marker for gastric cancer[6,7]. VEGFR2, the receptor of vascular endothelial growth factor (VEGF), is principally responsible for mediating the mitogenic-, angiogenic- and permeability-enhancing effects of VEGF and potentially plays a role in stimulating tumour growth and metastasis[8]. The expression of VEGFR2 might be a prognostic factor for gastric cancer, and the blockage of VEGFR2 in metastatic gastric cancers that progressed after fluoropyrimidine-based or platinum-based first-line chemotherapy has shown a survival benefit as a second-line treatment option[9,10]. It has been demonstrated that EGFR, a receptor tyrosine kinase, phosphorylates and regulates numerous cellular proteins and initiates several signal transduction cascades, leading to cell proliferation, migration, invasion, metastasis, angiogenesis and inhibition of apoptosis[11]. The EGFR expression level in gastric cancer is closely related to the incidence and development of gastric cancer, and it can provide a theoretical basis for the targeted therapy of gastric cancer positive for EGFR expression[12,13]. Currently, immunohistochemistry in surgical specimens is the gold standard to assess the status of the above biomarkers, but it is not suitable for gastric cancer patients with distant metastasis who lose the opportunity to undergo surgical resection. Tumour specimens obtained from endoscopic biopsy are also available for immunohistochemistry, but this process involves an invasive procedure that includes unavoidable sample errors. Endoscopic ultrasonography (EUS) and multi-detector row computed tomography (MDCT) are the main modalities used for detecting and assessing gastric cancer preoperatively. In addition, magnetic resonance imaging (MRI) also has shown a potential value, owing to its high soft tissue resolution and multiple sequences imaging, but it still has not been widely applied in clinical practice for the diagnosis and evaluation of gastric cancer preoperatively. EUS plays an important role in the preoperative T staging of gastric cancer, especially in distinguishing mucosal and submucosal cancers[14]. However, EUS is an invasive examination and deeply relies on the operator’s experience. CT and MRI are both non-invasive modalities that can objectively assess the lesion and its adjacent structures. Compared with MRI, CT imaging is a less time-consuming examination and is less susceptible to respiratory artefacts[15]. Therefore, CT is the most widely used preoperative staging modality in gastric cancer at present[16]. CT texture analysis is an adjunct tool involving the extraction of a large number of quantitative features from CT images to reflect the distribution and relationship of pixels. CT texture analysis not only detects subtle differences in pixels that cannot be recognized by the human eye but also assesses tumour heterogeneity, indirectly providing information of the tumour microenvironment[17]. CT tumour texture analysis has shown promise in predicting the pathologic features, overall survival and response to therapy in various tumours composing gastric cancer[18-24]. Giganti et al. demonstrated that pre-treatment CT texture analysis might be a good prognostic biomarker and provide valuable information regarding the response rate to neo-adjuvant therapy, reflecting the aggressiveness and risk stratification for gastric cancer[21,23]. Our previous study also suggested that CT texture analyses held great potential in predicting differentiation degrees, the Lauren classification score and vascular invasion status of gastric cancers. However, the correlation between CT texture features and immunohistochemical biomarkers in gastric cancer has not been documented. This study aimed to investigate the ability of CT texture analysis to assess and predict the expression levels of immunohistochemical biomarkers, including E-cadherin, Ki67, VEGFR2 and EGFR, in gastric cancer.

Results

The expression levels of immunohistochemical biomarkers

In our cohort, the rates of gastric cancers positive for E-cadherin, Ki67, VEGFR2 and EGFR expressions were 34.3% (35/102), 51.5% (70/136), 47.7% (63/132) and 32.8% (44/134), respectively. The ROI (region of interest) drawing and the averaged CT histograms in gastric cancers with different E-cadherin, Ki67, VEGFR2 and EGFR expression levels in the arterial and venous phases are shown in Figs 1 and 2, respectively.
Figure 1

A 66-year-old man with poorly differentiated gastric adenocarcinoma positive for E-cadherin expression (+++), negative for Ki67 expression (expression index: 50%), weakly positive for VEGFR2 expression and weakly positive for EGFR expression. Axial CT images in the (a) arterial and (b) venous phases show a thickened wall with remarkable enhancement in the lesser curvature of the stomach. Note the region of interest (ROI) covering the largest slice of the lesion.

Figure 2

Averaged CT histograms derived from the arterial (a,b,c,d) and venous (e,f,g,h) phases show different distributions of pixel intensity in gastric cancers with different E-cadherin, Ki67, VEGFR2 and EGFR expression levels.

A 66-year-old man with poorly differentiated gastric adenocarcinoma positive for E-cadherin expression (+++), negative for Ki67 expression (expression index: 50%), weakly positive for VEGFR2 expression and weakly positive for EGFR expression. Axial CT images in the (a) arterial and (b) venous phases show a thickened wall with remarkable enhancement in the lesser curvature of the stomach. Note the region of interest (ROI) covering the largest slice of the lesion. Averaged CT histograms derived from the arterial (a,b,c,d) and venous (e,f,g,h) phases show different distributions of pixel intensity in gastric cancers with different E-cadherin, Ki67, VEGFR2 and EGFR expression levels.

CT texture analysis in assessing E-cadherin expression in gastric cancer

Univariate analysis showed that the standard deviation (SD), width, entropy, entropy (H), correlation and contrast derived from the arterial and venous phases differed significantly between gastric cancers with positive and negative E-cadherin expressions (all P < 0.05). Spearman’s correlation test showed significant correlations between the above parameters and E-cadherin expression in gastric cancers (r = −0.250–0.327, all P < 0.05) (Table 1). Receiver operating characteristic (ROC) analysis showed that the above parameters could distinguish gastric cancers with positive E-cadherin expression from those with negative E-cadherin expression, and the area under the receiver operating characteristic curve (AUC) for these parameters ranged from 0.613–0.715 (all P < 0.05) (Table 2).
Table 1

Correlations between CT texture parameters and immunohistochemical markers of gastric cancers.

ParameterPhaseVEGFR2E-cadherinKi67
rP valuerP valuerP value
MeanArterial−0.1170.1820.0510.607−0.0380.664
SDArterial0.0150.8670.3130.001*−0.0910.291
SkewnessArterial0.0210.808−0.0280.776−0.1880.028*
KurtosisArterial−0.1100.208−0.0850.3960.0420.626
WidthArterial0.0270.7620.3270.001*−0.0940.276
EntropyArterial0.0240.7810.2810.004*−0.0900.297
Entropy(H)Arterial−0.0090.9180.2170.029*−0.0090.920
CorrelationArterial0.0800.362−0.2500.011*0.0100.909
AutocorrelationArterial−0.0990.2580.0860.391−0.0090.915
ContrastArterial0.0100.9060.3060.002*−0.0830.337
MeanVenous−0.0070.9360.0570.567−0.2120.013*
SDVenous0.1840.0350.2610.008*−0.1440.094
SkewnessVenous−0.0840.337−0.0180.8560.1010.240
KurtosisVenous−0.1220.164−0.1020.307−0.0590.493
WidthVenous0.1950.025*0.2460.013*−0.1310.130
EntropyVenous0.2130.014*0.2290.021*−0.1360.115
Entropy(H)Venous0.1090.2150.1550.121−0.0700.420
CorrelationVenous−0.0870.323−0.2000.044*0.0440.611
AutocorrelationVenous0.0270.7610.0780.433−0.2190.011*
ContrastVenous0.1870.032*0.2590.008*−0.1480.086

Note: r: correlation coefficient; SD: standard deviation; *P < 0.05.

Table 2

The diagnostic performance of CT texture parameters in predicting E−cadherin expression level in gastric cancers.

ParameterPhaseCut-offSen (%)Spe (%)Acc (%)AUCP value
SDArterial18.9248.683.671.60.698<0.001
Width#Arterial44.0054.376.168.60.715<0.001
EntropyArterial4.2848.685.172.60.687<0.001
entropy (H)Arterial7.1288.644.859.80.6750.001
CorrelationaArterial44.8488.641.857.80.685<0.001
AutocorrelationArterial166.9891.435.854.90.6130.047
ContrastArterial19.0751.480.670.60.702<0.001
SDVenous19.3262.965.764.70.6620.005
Width#Venous54.0045.777.666.70.6510.009
EntropyVenous4.3260.068.765.70.6430.013
entropy(H)Venous7.5382.944.857.90.6350.018
CorrelationaVenous28.2065.764.264.70.6510.008
ContrastVenous21.4065.761.262.70.6600.005

Note: Sen: sensitivity; Spe: specificity; Acc: accuracy; AUC: area under the receiver operating characteristic (ROC) curve; SD: standard deviation; #HU (Hounsfield unit); a × 10−3.

Correlations between CT texture parameters and immunohistochemical markers of gastric cancers. Note: r: correlation coefficient; SD: standard deviation; *P < 0.05. The diagnostic performance of CT texture parameters in predicting E−cadherin expression level in gastric cancers. Note: Sen: sensitivity; Spe: specificity; Acc: accuracy; AUC: area under the receiver operating characteristic (ROC) curve; SD: standard deviation; #HU (Hounsfield unit); a × 10−3.

CT texture analysis in assessing Ki67 expression in gastric cancer

Univariate analysis showed that skewness derived from the arterial phase, mean and autocorrelation derived from the venous phase differed significantly between gastric cancers with positive Ki67 expression and those with negative Ki67 expression (all P < 0.05). Spearman’s correlation test showed that skewness derived from the arterial phase, mean and autocorrelation derived from the venous phase were negatively correlated with the Ki67 expression level in gastric cancer (r = −0.188 to −0.219, all P < 0.05) (Table 1). ROC analysis showed that skewness derived from the arterial phase, mean and autocorrelation derived from the venous phase could distinguish gastric cancers with positive Ki67 expression from those with negative Ki67 expression (AUC = 0.621–0.647, all P < 0.05) (Table 3).
Table 3

The diagnostic performance of CT texture parameters in predicting VEGFR2 and Ki67 expression levels in gastric cancers.

ParametersCut-offSen (%)Spe (%)Acc (%)AUCP value
Ki67 + vs. −Skewness (A)−0.2145.786.465.40.6470.002
Mean# (V)86.7482.942.463.20.6210.013
Autocorrelation (V)470.0282.942.463.20.6210.013
VEGFR2 + vs. −SD (V)20.8141.381.262.10.6120.022
Entropy (V)4.3938.185.562.90.6260.010
Width# (V)53.0042.979.762.10.6200.014
Contrast (V)26.5839.782.662.10.6150.019

Note: A: arterial phase; V: venous phase; Sen: sensitivity; Spe: specificity; Acc: accuracy; AUC: area under the receiver operating characteristic (ROC) curve; +: positive expression; −: negative expression; SD: standard deviation; #HU (Hounsfield unit).

The diagnostic performance of CT texture parameters in predicting VEGFR2 and Ki67 expression levels in gastric cancers. Note: A: arterial phase; V: venous phase; Sen: sensitivity; Spe: specificity; Acc: accuracy; AUC: area under the receiver operating characteristic (ROC) curve; +: positive expression; −: negative expression; SD: standard deviation; #HU (Hounsfield unit).

CT texture analysis in assessing VEGFR2 expression in gastric cancer

Univariate analysis showed that the SD, width, entropy and contrast derived from the venous phase differed significantly between gastric cancer with positive VEGFR2 expression and those with negative VEGFR2 expression (all P < 0.05). Spearman’s correlation test indicated that width, entropy and contrast derived from the venous phase were positively correlated with the VEGFR2 expression level in gastric cancers (r = 0.187–0.213, all P < 0.05) (Table 1). ROC analysis showed that SD, width, entropy and contrast derived from the venous phase could distinguish gastric cancers with positive VEGFR2 expression from those with negative VEGFR2 expression (AUC = 0.612–0.626, all P < 0.05) (Table 3).

CT texture analysis in assessing EGFR expression in gastric cancer

None of the CT texture features differed significantly between gastric cancers with positive EGFR expression and those with negative EGFR expression.

Inter-observer agreement in the measurement of CT texture parameters

As shown in Table 4, mean, entropy (H), correlation and autocorrelation showed excellent inter-observer agreement (ICC = 0.850–0.940), while SD, width, entropy and contrast showed good inter-observer agreement (ICC = 0.757–0.792). However, skewness and kurtosis showed moderate inter-observer agreement (ICC = 0.551–0.595).
Table 4

Inter-observer agreement of CT texture parameters of gastric cancers.

ParameterICC in arterial phase (95% CI)ICC in venous phase (95% CI)
Mean0.940 (0.907–0.961)0.918 (0.874–0.947)
SD0.778 (0.659–0.856)0.757 (0.607–0.847)
Skewness0.586 (0.363–0.731)0.551 (0.310–0.708)
Kurtosis0.578 (0.351–0.726)0.595 (0.377–0.737)
Width0.786 (0.671–0.861)0.792 (0.680–0.865)
Entropy0.772 (0.649–0.852)0.744 (0.576–0.842)
Entropy(H)0.850 (0.769–0.902)0.878 (0.812–0.921)
Correlation0.868 (0.797–0.914)0.913 (0.867–0.944)
Autocorrelation0.869 (0.799–0.915)0.927 (0.888–0.953)
Contrast0.790 (0.677–0.863)0.780 (0.662–0.857)

Note: ICC: intra-class correlation coefficient; CI: confidence interval.

Inter-observer agreement of CT texture parameters of gastric cancers. Note: ICC: intra-class correlation coefficient; CI: confidence interval.

Discussion

Our study verified the correlation between CT texture features and immunohistochemical biomarkers, including E-cadherin, Ki67, VEGFR2 and EGFR, in gastric cancers, which has not been previously reported by any study until now. Our data showed that SD, width, entropy, entropy (H), correlation and contrast from the arterial and venous phases were significantly correlated with the expression of E-cadherin in gastric cancer. A lower SD and a shorter width indicated a more centralized distribution. Less entropy, less entropy (H), less contrast and a higher correlation implied a lower degree of chaos. Our data suggested that the grey-level distribution was more centralized and homogeneous in gastric cancers negative for E-cadherin expression. According to a previous study, CT texture analysis can be applied to assess histopathological features in gastric cancers. Gastric cancers of diffuse-type and with vascular invasion showed more homogeneous CT distributions (lower SD and entropy) than those of an intestinal-type and without vascular invasion[22]. Our data showed that SD and entropy were significantly lower in gastric cancers negative for E-cadherin expression than in those positive for E-cadherin expression. A previous meta-analysis[4] also found that gastric cancers of diffuse-type and with vascular invasion had a significant decrease in the E-cadherin expression compared to those of intestinal-type and without vascular invasion (OR = 4.22 and 1.86, respectively), which provided indirect evidence to confirm our findings. In our study, CT texture features performed well in distinguishing gastric cancers with positive expression of E-cadherin from those with negative expression of E-cadherin, with the AUCs ranging from 0.613 to 0.715. Compared with venous texture analysis, arterial texture analysis indicated a better predictive value. In addition, low expression of E-cadherin significantly predicted poor overall survival of gastric cancer patients (HR = 1.62, 95% CI: 1.34–1.96)[4]. Nevertheless, the prognostic value of CT texture analysis in gastric cancer still needs further investigation. Our data showed skewness in the arterial phase and mean and autocorrelation in the venous phase were all negatively with correlated the expression of Ki67 in gastric cancer. More negative skewness indicated that the grey-level intensity of lesions was more partial to a relatively high-density range. A lower value of autocorrelation implied a lower extent of similarity of CT values, indicating a more heterogeneous distribution of grey-level intensity. According to previous studies[25], CT arterial imaging might mainly reflect the blood supply and functional capillary density of gastric cancers, while venous imaging might reflect more dysfunctional neo-vessels and represent the distribution of contrast media in interstitial spaces. Our data suggested that the functional capillary density of lesions might be more abundant but dysfunctional neo-vessels might be reductive and more heterogeneous in gastric cancers positive for Ki67 expression. Few studies have reported the correlation of the CT performance and Ki67 expression in gastric carcinomas. Wang et al.[26] found that the Ki67 expression of gastric carcinomas was significantly correlated with the thickness of the tumour and lymph node metastasis from the CT findings, indicating that traditional CT images provided restricted value in assessing the Ki67 expression level. Ki67 has been declared as a predictor of cell proliferation and malignant potential in human malignancies[27]. The Ki67 expression level has potential to be a prognostic biomarker in gastric cancer[6,7]. CT texture analysis might serve as a more sensitive tool to assess Ki67 expression in gastric cancer. In our study, skewness from the arterial phase and mean and autocorrelation from the venous phase performed well in predicting the expression level of Ki67 in gastric cancer, with AUCs ranging from 0.621 to 0.647. We also found that there were higher values of SD, width, entropy and contrast in venous phase analysis in gastric cancer positive for VEGFR2 expression compared to in that negative for VEGFR2 expression, indicating that the distribution of dysfunctional neo-vessels might be more heterogeneous in lesions with positive VEGFR2 expression. VEGF and its receptor, VEGFR2, might compose the important receptor-ligand system in the process of angiogenesis in gastric cancer[9]. Additionally, targeting VEGFR2 was also considered a promising therapeutic strategy with regard to angiogenesis for gastric cancer[28]. SD, width, entropy and contrast derived from the venous phase proved useful in differentiating gastric cancers positive for VEGFR2 expression from those negative for VEGFR2 expression, despite of the weak predictive value with its highest AUC of 0.626. Our data showed no significant association between the CT texture features and the EGFR expression in gastric cancers. There have been several studies on CT texture parameters related to the EGFR mutation status in lung adenocarcinomas[29,30]. Our preliminary findings suggested that CT texture analysis could have few potential applications in assessing the expression of EGFR in gastric cancer. Anyway, EGFR plays different roles in gastric cancers and lung adenocarcinomas[12,31]. The inter-observer agreement of most texture parameters was well to excellent. The inter-observer agreement of skewness and kurtosis in both the arterial and venous phases was worse than that of the other parameters. Additionally, the inter-observer agreement of the second-order features seemed to be better than most first-order features, indicating that the second-order features are more reliable and repeatable.

Limitations

Our study had a few limitations. First, the CT images of the gastric cancer patients were retrospectively obtained from several CT scanners. Nevertheless, a good inter-scanner agreement of the CT texture analysis was confirmed[32]. Second, unenhanced CT images were not enrolled into our study cohort for texture analysis because it is difficult to identify tumour margins exactly on unenhanced images, despite their potential value[33]. Finally, the largest slice of the lesion, rather than the whole lesion (i.e., contouring the lesion slice by slice), was selected for texture analysis, which might not have adequately represented the heterogeneous characteristics of the lesions. However, several previous studies suggested that the comparison of single-level and whole-tumour texture analyses of single lesions showed fairly comparable results[32,34]. In addition, the ROIs outlining the area of greatest enhancement could minimize the effect of necrotic tissues and reflect angiogenesis more intensively, but there might exist site-by-site biases when placing ROIs[35,36]. In contrast, largest-level texture analysis might accurately reflect the heterogeneity of the whole lesion and improve the repeatability and reproducibility of texture analysis.

Conclusion

CT texture analysis might serve as a promising non-invasive diagnostic tool to predict immunohistochemical biomarkers, including E-cadherin, Ki67 and VEGFR2, in gastric cancers, indirectly reflecting the ability of tumour migration, proliferation and angiogenesis.

Materials and Methods

Patients

This retrospective study was approved by the ethics committee of the Institutional Review Board of Nanjing Drum Tower Hospital, and the requirement for informed consent was waived. We collected data from and analysed a total of 264 patients with a clinical diagnosis of gastric cancer between January 2014 and December 2016. The inclusion criteria were: (1) with biopsy-proven gastric cancer; (2) with an identifiable lesion in contrast-enhanced CT images before surgery; (3) with a curative or palliative gastrectomy in our hospital. The exclusion criteria were: (1) with any local or systematic treatment before surgery (n = 37); (2) with difficulty in outlining the margin due to it having too small of a size (the maximum diameter <1 cm) (n = 52); (3) with a previous partial gastrectomy (n = 19); (4) without a definite location or margin due to no contrast or poor contrast of the lesion in the enhanced CT image (n = 12); (5) without available immunohistochemical markers (n = 5). Eventually, a total of 139 patients (age: 29–92 years; median age: 63 years) were enrolled in our study cohort, and the clinicopathological variables of the patients are presented in Table 5.
Table 5

Clinicopathological features of 139 patients with gastric cancer.

Featuren (percentage)
Gender
  Male103 (74.1%)
  Female36 (25.9%)
Age
  <60 years41 (29.5%)
  ≥60 years98 (70.5%)
Major location
  Cardia and fundus51 (36.7%)
  Body34 (24.5%)
  Antrum54 (38.8%)
Siewert classification
  Siewert I0 (0)
  Siewert II24 (47.1%)
  Siewert III27 (52.9%)
Main pathological type
  Tubular or papillary adenocarcinoma111 (79.9%)
  Poorly cohesive adenocarcinoma22 (15.8%)
  Signet-ring cell carcinoma6 (4.3%)
Differentiation degree
  Poor113 (81.3%)
  Moderate/well26 (18.7%)
Lauren classification
  Diffuse type43 (30.9%)
  Mixed type39 (28.1%)
  Intestinal type57 (41.0%)
T stage
  ≤T28 (5.7%)
  T381 (58.3%)
  T450 (36.0%)
N stage
  N020 (14.4%)
  N1–3119 (85.6%)
M stage
  M0133 (95.7%)
  M16 (4.3%)

Note: TNM stage was classified based on the 7th edition of the AJCC classification system.

Clinicopathological features of 139 patients with gastric cancer. Note: TNM stage was classified based on the 7th edition of the AJCC classification system.

CT image acquisition

All CT examinations were performed on a 16- or 64-slice scanner (Light Speed Pro 16, VCT, or Discovery HD 750, GE Healthcare, US). Before the examination, all patients signed the informed consent, were requested to fast from solid food for at least six hours and received 600–1000 mL water orally to achieve gastric distension. All patients were in the supine position during the scan, and the scan covered the upper or the entire abdomen. The patients were trained to hold their breath during the CT scanning. Following the non-contrast scan, 1.5 mL/kg iodinated contrast agent (Omnipaque 350 mg I/mL, GE Healthcare, Shanghai, China) was injected intravenously, at a flow rate of 3.0 mL/s, by using a high-pressure syringe (Medrad Stellant CT injector system; One Medrad Drive Indianola, PA, US). Imaging was obtained with post-injection delays of 30 seconds and 70 seconds, corresponding to the arterial and venous phases, respectively, after initiation of the contrast material injection. The CT scanning parameters were: tube voltage: 120 kVp, tube current: 250–350 mA, slice thickness: 5 mm, slice interval: 5 mm, field of view: 35–50 cm, matrix: 512 × 512, rotation time: 0.7 s, and pitch: 1.375. The mean interval between CT examination and surgery was 5 days (range: 1–10 days).

CT texture analysis

Texture analysis was performed via an in-house software (Image Analyser 2.0, China). Manual recognition of gastric cancers was performed by a radiologist (S.L., with 5 years of experience in gastroenterology imaging) and confirmed by one abdominal radiologist (Z.Y.Z., with 11 years of experience in gastroenterology imaging), who were both blinded to the clinicopathological information of the patient. The lesions of gastric cancers on enhanced CT images were defined as focal thickening with obvious enhancement of the gastric wall. According to the literature[37], focal thickening of the gastric wall by 6 mm or greater, compared with that of the adjacent gastric wall, was determined to be abnormal thickening and cancerous. A polygonal ROI (arterial phase CT images: mean area: 712.0 mm2, range: 94.1–2506.4 mm2; venous phase CT images: mean area: 716.6 mm2, range: 124.5–2459.2 mm2) was manually drawn along the margin of the lesion on the largest slice, carefully avoiding the gastric lumen and artefacts. The texture features were generated automatically from the above ROIs of CT images using the in-house software: (1) the first-order features describing the distribution of pixel intensity within the ROIs, including mean (mean pixel intensity), SD (standard deviation, spread of the distribution), skewness (asymmetry of a histogram), kurtosis (peakness or pointedness of a histogram), width (width between the 10th and 90th percentiles of intensity of a histogram) and entropy (irregularity or complexity of pixel intensities); (2) the second-order features were from the grey-level co-occurrence matrix (GLCM), including entropy (H), correlation, autocorrelation and contrast. The normalized GLCM element can describe the probability of a pair of grey levels that are separated by a certain distance in a certain direction, providing spatial information of the pixel distribution. In this study, the distance of the pair was one pixel, and the directions were 0°, 45°, 90° and 135°, respectively. We took the average values of GLCMs in the four directions as the final values of the second-order features. The formulas of the first-order entropy and the second-order features are shown in Supplementary Methods. Additionally, another abdominal radiologist (J.H., with 8 years of experience in gastroenterology imaging) performed manual recognition independently to evaluate the inter-observer variability of manual recognition in calculating the texture features of gastric cancers. All image analyses and calculations were performed separately for the CT images of the arterial and venous phases.

Immunohistochemical evaluation

Immunohistochemical analysis was used to evaluate the expression of different markers, including E-cadherin, Ki67, VEGFR2 and EGFR. A pathologist (L.C.) with 7 years of experience in gastrointestinal pathology, who was blinded to the clinical information, including name, gender and age, of the patient, carefully reviewed the slides from each sample and assessed the extent of immunohistochemical staining. The expression levels of E-cadherin were divided into four groups according to the percentages of E-cadherin-positive cells, as described previously[38]: 0: <10% of positive cells; 1+: 10–30% of positive cells; 2+: 30–60% of positive cells; 3+: >60% of positive cells. Samples with grade 0 or 1 + E-cadherin expression level were categorized as having negative staining[39]. The Ki67 labelling index was estimated by evaluating the nuclear immunoreactivity of 1000 tumour cells in ten random fields at high magnification and calculating the percentage of cells with positive nuclear staining relative to all tumour cell nuclei in the area examined. More than 50% positive staining in the nucleus was defined as positive Ki67 staining[39]. For the VEGFR2 expression level, the cases were scored based on the staining intensity and percentage of cells stained, similarly to previous studies[40]. Staining intensity was graded from 0 to 3 (0 = none; 1 = weak; 2 = moderate; and 3 = strong). The percentage of immunopositive cells was given a score from 0–3 (0: 0% immunopositive cells; 1: 1–25% immunopositive cells; 2: 26–50% immunopositive cells; 3: >50% immunopositive cells). According to the sum of the intensity and percentage, the expression of VEGFR2 was divided into three levels: scores of 0 and 2 were regarded as negative for VEGFR2 expression, scores of 3 and 4 as weakly positive, and scores of 5 and 6 as strongly positive. The expression level of EGFR was graded from 0 to 3+: 0: no staining or membranous reactivity in <10% of tumour cells; 1+: weak, barely perceptible membranous reactivity in >10% of tumour cells; 2+: complete or basolateral membranous reactivity of either a non-uniform or weak intensity in at least 10% of cells; 3+: complete or basolateral membranous reactivity of a strong intensity in ≥10% of cells[13]. Patients with grade 0 were categorized as having negative staining.

Statistical analyses

The normality distribution of CT texture parameters was evaluated by the Kolmogorov-Smirnov normality test. Based on the normality test results, univariate analysis was performed by the Mann-Whitney U test for CT texture parameters of gastric cancers with different immunohistochemical features. Relationships between CT texture features and immunohistochemical markers were assessed by the Spearman correlation test. The diagnostic performance of CT texture parameters in predicting expression levels of immunohistochemical markers was evaluated with ROC analysis. Inter-observer agreement in the measurements of CT texture parameters was estimated with the intra-class correlation coefficient (ICC) (0.000–0.400: poor; 0.401–0.600: moderate; 0.601–0.800: well; 0.801–1.000: excellent). ROC analysis was performed with MedCalc version 15.2.2 statistical software (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2015), and other statistical analyses were performed with SPSS (version 22.0 for Microsoft Windows x64, SPSS, Chicago, US). A two-tailed P value less than 0.05 was considered statistically significant.

Data Availability

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request. Supplementary Methods
  40 in total

1.  Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma.

Authors:  Y Yokoyama; S Sato; M Futagami; Y Fukushi; T Sakamoto; M Umemoto; Y Saito
Journal:  Gynecol Oncol       Date:  2000-06       Impact factor: 5.482

Review 2.  Hypervascular gastric masses: CT findings and clinical correlates.

Authors:  Pamela T Johnson; Karen M Horton; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2010-12       Impact factor: 3.959

Review 3.  Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies.

Authors:  J Gerdes
Journal:  Semin Cancer Biol       Date:  1990-06       Impact factor: 15.707

4.  Extent of arterial tumor enhancement measured with preoperative MDCT gastrography is a prognostic factor in advanced gastric cancer after curative resection.

Authors:  Masahiro Komori; Yoshiki Asayama; Nobuhiro Fujita; Kiyohisa Hiraka; Daisuke Tsurumaru; Yoshihiro Kakeji; Hiroshi Honda
Journal:  AJR Am J Roentgenol       Date:  2013-08       Impact factor: 3.959

Review 5.  Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.

Authors:  Giandomenico Roviello; Andrea Ravelli; Karol Polom; Roberto Petrioli; Luigi Marano; Daniele Marrelli; Franco Roviello; Daniele Generali
Journal:  Cancer Lett       Date:  2016-01-18       Impact factor: 8.679

Review 6.  CT Texture Analysis: Definitions, Applications, Biologic Correlates, and Challenges.

Authors:  Meghan G Lubner; Andrew D Smith; Kumar Sandrasegaran; Dushyant V Sahani; Perry J Pickhardt
Journal:  Radiographics       Date:  2017 Sep-Oct       Impact factor: 5.333

7.  Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.

Authors:  Y Takahashi; K R Cleary; M Mai; Y Kitadai; C D Bucana; L M Ellis
Journal:  Clin Cancer Res       Date:  1996-10       Impact factor: 12.531

8.  CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung.

Authors:  Efe Ozkan; Anna West; Jeffrey A Dedelow; Benjamin F Chu; Weiqiang Zhao; Vedat O Yildiz; Gregory A Otterson; Konstantin Shilo; Subha Ghosh; Mark King; Richard D White; Barbaros S Erdal
Journal:  AJR Am J Roentgenol       Date:  2015-11       Impact factor: 3.959

9.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Christine Allen; Ryan M Barber; Lars Barregard; Zulfiqar A Bhutta; Hermann Brenner; Daniel J Dicker; Odgerel Chimed-Orchir; Rakhi Dandona; Lalit Dandona; Tom Fleming; Mohammad H Forouzanfar; Jamie Hancock; Roderick J Hay; Rachel Hunter-Merrill; Chantal Huynh; H Dean Hosgood; Catherine O Johnson; Jost B Jonas; Jagdish Khubchandani; G Anil Kumar; Michael Kutz; Qing Lan; Heidi J Larson; Xiaofeng Liang; Stephen S Lim; Alan D Lopez; Michael F MacIntyre; Laurie Marczak; Neal Marquez; Ali H Mokdad; Christine Pinho; Farshad Pourmalek; Joshua A Salomon; Juan Ramon Sanabria; Logan Sandar; Benn Sartorius; Stephen M Schwartz; Katya A Shackelford; Kenji Shibuya; Jeff Stanaway; Caitlyn Steiner; Jiandong Sun; Ken Takahashi; Stein Emil Vollset; Theo Vos; Joseph A Wagner; Haidong Wang; Ronny Westerman; Hajo Zeeb; Leo Zoeckler; Foad Abd-Allah; Muktar Beshir Ahmed; Samer Alabed; Noore K Alam; Saleh Fahed Aldhahri; Girma Alem; Mulubirhan Assefa Alemayohu; Raghib Ali; Rajaa Al-Raddadi; Azmeraw Amare; Yaw Amoako; Al Artaman; Hamid Asayesh; Niguse Atnafu; Ashish Awasthi; Huda Ba Saleem; Aleksandra Barac; Neeraj Bedi; Isabela Bensenor; Adugnaw Berhane; Eduardo Bernabé; Balem Betsu; Agnes Binagwaho; Dube Boneya; Ismael Campos-Nonato; Carlos Castañeda-Orjuela; Ferrán Catalá-López; Peggy Chiang; Chioma Chibueze; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Solomon Damtew; José das Neves; Suhojit Dey; Samath Dharmaratne; Preet Dhillon; Eric Ding; Tim Driscoll; Donatus Ekwueme; Aman Yesuf Endries; Maryam Farvid; Farshad Farzadfar; Joao Fernandes; Florian Fischer; Tsegaye Tewelde G/Hiwot; Alemseged Gebru; Sameer Gopalani; Alemayehu Hailu; Masako Horino; Nobuyuki Horita; Abdullatif Husseini; Inge Huybrechts; Manami Inoue; Farhad Islami; Mihajlo Jakovljevic; Spencer James; Mehdi Javanbakht; Sun Ha Jee; Amir Kasaeian; Muktar Sano Kedir; Yousef S Khader; Young-Ho Khang; Daniel Kim; James Leigh; Shai Linn; Raimundas Lunevicius; Hassan Magdy Abd El Razek; Reza Malekzadeh; Deborah Carvalho Malta; Wagner Marcenes; Desalegn Markos; Yohannes A Melaku; Kidanu G Meles; Walter Mendoza; Desalegn Tadese Mengiste; Tuomo J Meretoja; Ted R Miller; Karzan Abdulmuhsin Mohammad; Alireza Mohammadi; Shafiu Mohammed; Maziar Moradi-Lakeh; Gabriele Nagel; Devina Nand; Quyen Le Nguyen; Sandra Nolte; Felix A Ogbo; Kelechi E Oladimeji; Eyal Oren; Mahesh Pa; Eun-Kee Park; David M Pereira; Dietrich Plass; Mostafa Qorbani; Amir Radfar; Anwar Rafay; Mahfuzar Rahman; Saleem M Rana; Kjetil Søreide; Maheswar Satpathy; Monika Sawhney; Sadaf G Sepanlou; Masood Ali Shaikh; Jun She; Ivy Shiue; Hirbo Roba Shore; Mark G Shrime; Samuel So; Samir Soneji; Vasiliki Stathopoulou; Konstantinos Stroumpoulis; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Fentaw Tadese; Bemnet Amare Tedla; Gizachew Assefa Tessema; J S Thakur; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Benjamin S Chudi Uzochukwu; Vasiliy Victorovich Vlassov; Elisabete Weiderpass; Mamo Wubshet Terefe; Henock Gebremedhin Yebyo; Hassen Hamid Yimam; Naohiro Yonemoto; Mustafa Z Younis; Chuanhua Yu; Zoubida Zaidi; Maysaa El Sayed Zaki; Zerihun Menlkalew Zenebe; Christopher J L Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

10.  The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer.

Authors:  Akin Atmaca; Dominique Werner; Claudia Pauligk; Kristina Steinmetz; Ralph Wirtz; Hans-Michael Altmannsberger; Elke Jäger; Salah-Eddin Al-Batran
Journal:  BMC Cancer       Date:  2012-11-15       Impact factor: 4.430

View more
  10 in total

Review 1.  Does radiomics play a role in the diagnosis, staging and re-staging of gastroesophageal junction adenocarcinoma?

Authors:  Martina Mori; Diego Palumbo; Francesco De Cobelli; Claudio Fiorino
Journal:  Updates Surg       Date:  2022-09-17

2.  Expression of M3 muscarinic acetylcholine receptors in gastric cancer.

Authors:  Alina Maria Mehedinţeanu; Cecil Sorin Mirea; Puiu Olivian Stovicek; Michael Schenker; Marius Ionuţ Stancu; Ana Maria Ciurea; Liliana Streba; Anca Maria Istrate-Ofiţeru; Teodor Nicuşor Sas; Cristin Constantin Vere
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

Review 3.  Predicting cancer outcomes with radiomics and artificial intelligence in radiology.

Authors:  Kaustav Bera; Nathaniel Braman; Amit Gupta; Vamsidhar Velcheti; Anant Madabhushi
Journal:  Nat Rev Clin Oncol       Date:  2021-10-18       Impact factor: 65.011

4.  Acute Tumor Transition Angle on Computed Tomography Predicts Chromosomal Instability Status of Primary Gastric Cancer: Radiogenomics Analysis from TCGA and Independent Validation.

Authors:  Ying-Chieh Lai; Ta-Sen Yeh; Ren-Chin Wu; Cheng-Kun Tsai; Lan-Yan Yang; Gigin Lin; Michael D Kuo
Journal:  Cancers (Basel)       Date:  2019-05-09       Impact factor: 6.639

Review 5.  Imaging biomarkers in upper gastrointestinal cancers.

Authors:  Michela Gabelloni; Lorenzo Faggioni; Emanuele Neri
Journal:  BJR Open       Date:  2019-06-24

6.  Potential Value of Radiomics in the Identification of Stage T3 and T4a Esophagogastric Junction Adenocarcinoma Based on Contrast-Enhanced CT Images.

Authors:  Xu Chang; Xing Guo; Xiaole Li; Xiaowei Han; Xiaoxiao Li; Xiaoyan Liu; Jialiang Ren
Journal:  Front Oncol       Date:  2021-03-03       Impact factor: 6.244

7.  Segmentation of Gastric Computerized Tomography Images under Intelligent Algorithms in Evaluation of Efficacy of Decitabine Combined with Paclitaxel in Treatment of Gastric Cancer.

Authors:  Zhenghui Ge; Mengyun Wang; Qun Liu
Journal:  J Healthc Eng       Date:  2021-10-27       Impact factor: 2.682

8.  Development and validation of multivariate models integrating preoperative clinicopathological and radiographic findings to predict HER2 status in gastric cancer.

Authors:  Mengying Xu; Song Liu; Lin Li; Xiangmei Qiao; Changfeng Ji; Lingyu Tan; Zhengyang Zhou
Journal:  Sci Rep       Date:  2022-08-19       Impact factor: 4.996

9.  Evaluation of Epidermal Growth Factor Receptor 2 Status in Gastric Cancer by CT-Based Deep Learning Radiomics Nomogram.

Authors:  Xiao Guan; Na Lu; Jianping Zhang
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

10.  A CT-based radiomics nomogram for prediction of human epidermal growth factor receptor 2 status in patients with gastric cancer.

Authors:  Yexing Li; Zixuan Cheng; Olivier Gevaert; Lan He; Yanqi Huang; Xin Chen; Xiaomei Huang; Xiaomei Wu; Wen Zhang; Mengyi Dong; Jia Huang; Yucun Huang; Ting Xia; Changhong Liang; Zaiyi Liu
Journal:  Chin J Cancer Res       Date:  2020-02       Impact factor: 5.087

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.